As a AIDS compound preparation, Triumeq can be taken for a long time under the guidance of professional doctors, but its efficacy and safety need to be monitored regularly. The feasibility of long-term use is mainly based on the comprehensive evaluation of drug characteristics, clinical research data, and individual patient conditions.

Feasibility of long-term medication

(1) Drug characteristics: Suimeikai contains Doitavir, Abacavir, and Lamivudine, all of which are antiretroviral drugs that require long-term use.

(2) Clinical data: Multiple studies worldwide have confirmed its long-term efficacy and safety, with some patients taking the medication for more than 5 years.

2 Long term medication precautions

(1) Regular monitoring: HIV viral load, CD4 cell count, and liver and kidney function should be tested every 3-6 months.

(2) Adverse reaction management: Long term use may increase the risk of dyslipidemia, osteoporosis, and other conditions, requiring targeted intervention.

Long term medication for special populations

(1) Elderly patients: It is necessary to strengthen renal function monitoring and adjust the dosage if necessary.

(2) Patients with hepatitis B: when stopping the lamivudine component, be alert to the recurrence of hepatitis B.

4. Medication compliance requirements

(1) Strictly take medication on time: Omitting medication may lead to virus resistance and affect long-term efficacy.

(2) Lifelong treatment principle: at present, AIDS still needs to take medicine for life, and you cannot stop taking medicine without authorization.